文献速递急性肾损伤血液净化与透析

超滤装置在儿童肾脏支持中的应用:多中心回顾性研究

Kidney Support in Children using an Ultrafiltration Device: A Multicenter, Retrospective Study.
PubMed 文献 · Clin J Am Soc Nephrol · 2019-08-28

该多中心回顾性病例系列纳入119例次住院、884个循环的儿童,使用超滤装置提供肾脏替代治疗,按体重分组并采用三种模式。主要结局为肾脏替代治疗结束时存活率,体重<10 kg组存活率60%,>20 kg组为97%,治疗启动时心血管并发症发生率为3%且均不严重,治疗期间并发症发生率为15%且多为血管通路相关。

要点

  • 体重<10 kg患儿肾脏替代治疗结束时存活率低于>20 kg患儿(60% vs 97%)。
  • 体重<10 kg组主要采用连续性静脉-静脉血液滤过(CVVH,66%),>20 kg组以缓慢连续超滤为主。
  • 治疗启动时心血管并发症发生率3%且无严重事件,治疗期间并发症发生率15%且多为血管通路相关。

核心结论

  • 首次报告儿童使用超滤装置提供CVVH、延长的间歇性肾脏替代治疗和缓慢连续超滤的经验,尤其在危重新生儿中启动肾脏替代治疗并发症较少。

研究设计与样本

  • 多中心回顾性病例系列,纳入119例次住院、884个循环的接受超滤装置肾脏替代治疗的儿童,按体重(<10、10-20、>20 kg)分组并接受三种模式之一。

主要发现

  • 体重<10 kg组主要适应症为急性肾损伤(40%)、容量超负荷(46%)和终末期肾病(14%)。
  • 体重<10 kg组主要接受CVVH(66%,n=48)和延长的间歇性肾脏替代治疗(21%,n=15)。
  • 体重>20 kg组容量超负荷为主要适应症(91%),缓慢连续超滤为最常见模式。
  • 体重<10 kg组肾脏替代治疗结束时存活率低于>20 kg组(60% vs 97%),且启动时容量超负荷更重、治疗持续时间更长。
  • 治疗启动时心血管并发症发生率为3%且均不严重;治疗期间并发症发生率为15%,多数为血管通路相关。

临床怎么用

  • 在危重小体重患儿中可考虑使用低体外容量的超滤装置启动肾脏替代治疗,启动时心血管并发症较少。
  • 需关注小体重患儿肾脏替代治疗期间血管通路相关并发症。

局限性

  • 回顾性研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Provision of kidney replacement therapy (KRT) to manage kidney injury and volume overload in critically ill neonates and small children is technically challenging. The use of machines designed for adult-sized patients, necessitates large catheters, a high extracorporeal volume relative to patient size, and need for blood priming. The Aquadex FlexFlow System (CHF Solutions Inc., Eden Prairie, MN) is an ultrafiltration device designed for fluid removal in adults with diuretic resistant heart failure. It has an extracorporeal volume of 33 ml, which can potentially mitigate some complications seen at onset of KRT in smaller infants. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this multicenter, retrospective case series of children who received KRT with an ultrafiltration device (n=119 admissions, 884 circuits), we report demographics, circuit characteristics, complications, and short- and long-term outcomes. Patients were grouped according to weight (<10, 10-20, and >20 kg), and received one of three modalities: slow continuous ultrafiltration, continuous venovenous hemofiltration (CVVH), or prolonged intermittent KRT. Our primary outcome was survival to end of KRT. RESULTS: Treatment patterns and outcomes varied between the groups. In patients who weighed <10 kg, the primary indication was AKI in 40%, volume overload in 46%, and ESKD in 14%. These patients primarily received CVVH (66%, n=48) and prolonged intermittent KRT (21%, n=15). In the group weighing >20 kg, volume overload was the primary indication in 91% and slow continuous ultrafiltration was the most common modality. Patients <10 kg had lower KRT survival than those >20 kg (60% versus 97%), more volume overload at onset, and received KRT for a longer duration. Cardiovascular complications at initiation were seen in 3% of treatments and none were severe. Complications during therapy were seen in 15% treatments and most were vascular access-related. CONCLUSIONS: We report the first pediatric experience using an ultrafiltration device to provide a range of therapies, including CVVH, prolonged intermittent KRT, and slow continuous ultrafiltration. We were able to initiate KRT with minimal complications, particularly in critically ill neonates. There is an unmet need for devices specifically designed for younger patients. Having size-appropriate machines will improve the care of smaller children who require kidney support.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Menon S, Broderick J, Munshi R, et al. Kidney Support in Children using an Ultrafiltration Device: A Multicenter, Retrospective Study. Clin J Am Soc Nephrol. 2019. PMID: 31462396. doi:10.2215/CJN.03240319

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。